Similar Papers

Paper Title
Journal
Date
Author
Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Nitin Jain ... William G Wierda
Blood | VOL. 142
Nitin Jain, et. al.Nitin Jain ... William G Wierda
28 Nov 2023
The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia
Sean D Reiff ... Jennifer A Woyach
Blood | VOL. 128
Sean D Reiff, et. al.Sean D Reiff ... Jennifer A Woyach
02 Dec 2016
The Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL
Jennifer A Woyach ...
Blood | VOL. 128
Jennifer A Woyach, et. al.Jennifer A Woyach ...
02 Dec 2016
LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL
Aishath S Naeem ... Jennifer R Brown
Blood | VOL. 134
Aishath S Naeem, et. al.Aishath S Naeem ... Jennifer R Brown
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
A natural head start to MRD negativity in multiple myeloma.
Erin W Meermeier
Blood | VOL. 145
Erin W MeermeierErin W Meermeier
19 Jun 2025
Disrupting HIT immune complexes as a new treatment for HIT.
Beng H Chong
Blood | VOL. 145
Beng H ChongBeng H Chong
19 Jun 2025
Socioeconomic factors and transplant access.
-
Blood | VOL. 145
--
19 Jun 2025
TNFα signaling restores steady-state hematopoiesis in a TNFαKO mouse model of anemia of inflammation.
Amaliris Guerra ... Stefano Rivella
Blood | VOL. -
Amaliris Guerra, et. al.Amaliris Guerra ... Stefano Rivella
13 Jun 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.